CTRI/2026/07/114050进行中（未招募）2 期
A phase-II study of low-dose nivolumab as consolidation after concurrent chemoradiotherapy in unresectable EGFR/ALK negative stage-III non-small cell lung cancer in a resource-limited setting:LunAR-LoNivo - LunAR-LoNivo
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients aged 18-80 years of age, Histologically documented stage III non-small cell lung cancer, Deemed inoperable and treated with concurrent chemoradiotherapy, Post CTRT, has a documented response of complete response, partial response, or stable disease, as per RECIST 1.1 criteria, PS 0-2, Patients cannot afford consolidation immunotherapy with Durvalumab which is the international standard of care, Negative urine pregnancy test
排除标准
- •EGFR mutation or ALK fusion detected by polymerase chain reaction, immunohistochemistry, or next-generation sequencing, Has an underlying autoimmune disease, Has an untreated grade-2 or higher pneumonitis, Patients receiving systemic corticosteroids
研究者
相似试验
已完成
1 期
Phase 1 study of NG-641 plus nivolumab (or standard of care PD-1) in metastatic or advanced epithelial tumours (NEBULA)2023-503525-19-00Akamis Bio Limited85
Enrolling By Invitation
2 期
Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR CancersColorectal CancerGastric CancerNCT07542262Blokhin's Russian Cancer Research Center128
尚未招募
2 期
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO TrialHodgkin LymphomaNCT07576725Fred Hutchinson Cancer Center50
招募中
2 期
Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHLHodgkin LymphomaNCT07551583M.D. Anderson Cancer Center15
招募中
3 期
CheckMate 901: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9012022-501784-40-00Bristol Myers Squibb International Corporation701